A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors

Arun Rajan, Corey A. Carter, Ronan Joseph Kelly, Martin Gutierrez, Shivaani Kummar, Eva Szabo, Mary Ann Yancey, Uping Ji, Baskar Mannargudi, Sukyung Woo, Shawn Spencer, William Douglas Figg, Giuseppe Giaccone

Research output: Contribution to journalArticle

Abstract

Purpose: To determine the safety and tolerability of olaparib with cisplatin and gemcitabine, establish the maximum tolerated dose (MTD), and evaluate the pharmacodynamic and pharmacokinetic profile of the combination. Experimental Design: We conducted a phase I study of olaparib with cisplatin and gemcitabine in patients with advanced solid tumors. Treatment at dose level 1 (DL1) consisted of olaparib 100 mg orally every 12 hours on days 1 to 4, gemcitabine 500 mg/m 2 on days 3 and 10, and cisplatin 60 mg/m 2 on day 3. PAR levels were measured in peripheral blood mononuclear cells (PBMC). Results: Dose-limiting toxicities (DLT) in two of three patients at DL1 included thrombocytopenia and febrile neutropenia. The protocol was amended to enroll patients treated with ≤2 prior severely myelosuppressive chemotherapy regimens and treated with olaparib 100mgonce daily on days 1 to 4 (DL-1).No DLTs were seen in six patients at DL-1. Because of persistent thrombocytopenia and neutropenia following a return to DL1, patients received 100 mg olaparib every 12 hours on day 1 only. No hematologic DLTs were observed; nonhematologic DLTs included gastrointestinal bleed, syncope, and hypoxia. Of 21 patients evaluable for response, two had partial response. Olaparib inhibited PARP in PBMCs and tumor tissue, although PAR levels were less effectively inhibited when olaparib was used for a short duration. Conclusions: Olaparib in combination with cisplatin and gemcitabine is associated with myelosuppression even at relatively low doses. Modified schedules of olaparib in chemotherapy naive patients will have to be explored with standard doses of chemotherapy.

Original languageEnglish (US)
Pages (from-to)2344-2351
Number of pages8
JournalClinical Cancer Research
Volume18
Issue number8
DOIs
StatePublished - Apr 15 2012
Externally publishedYes

Fingerprint

gemcitabine
Cisplatin
Neoplasms
Drug Therapy
olaparib
Febrile Neutropenia
Maximum Tolerated Dose
Syncope
Neutropenia
Thrombocytopenia

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Rajan, A., Carter, C. A., Kelly, R. J., Gutierrez, M., Kummar, S., Szabo, E., ... Giaccone, G. (2012). A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors. Clinical Cancer Research, 18(8), 2344-2351. https://doi.org/10.1158/1078-0432.CCR-11-2425

A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors. / Rajan, Arun; Carter, Corey A.; Kelly, Ronan Joseph; Gutierrez, Martin; Kummar, Shivaani; Szabo, Eva; Yancey, Mary Ann; Ji, Uping; Mannargudi, Baskar; Woo, Sukyung; Spencer, Shawn; Figg, William Douglas; Giaccone, Giuseppe.

In: Clinical Cancer Research, Vol. 18, No. 8, 15.04.2012, p. 2344-2351.

Research output: Contribution to journalArticle

Rajan, A, Carter, CA, Kelly, RJ, Gutierrez, M, Kummar, S, Szabo, E, Yancey, MA, Ji, U, Mannargudi, B, Woo, S, Spencer, S, Figg, WD & Giaccone, G 2012, 'A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors', Clinical Cancer Research, vol. 18, no. 8, pp. 2344-2351. https://doi.org/10.1158/1078-0432.CCR-11-2425
Rajan, Arun ; Carter, Corey A. ; Kelly, Ronan Joseph ; Gutierrez, Martin ; Kummar, Shivaani ; Szabo, Eva ; Yancey, Mary Ann ; Ji, Uping ; Mannargudi, Baskar ; Woo, Sukyung ; Spencer, Shawn ; Figg, William Douglas ; Giaccone, Giuseppe. / A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors. In: Clinical Cancer Research. 2012 ; Vol. 18, No. 8. pp. 2344-2351.
@article{7bf51d75b48040d48d6ef46fa6c77b24,
title = "A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors",
abstract = "Purpose: To determine the safety and tolerability of olaparib with cisplatin and gemcitabine, establish the maximum tolerated dose (MTD), and evaluate the pharmacodynamic and pharmacokinetic profile of the combination. Experimental Design: We conducted a phase I study of olaparib with cisplatin and gemcitabine in patients with advanced solid tumors. Treatment at dose level 1 (DL1) consisted of olaparib 100 mg orally every 12 hours on days 1 to 4, gemcitabine 500 mg/m 2 on days 3 and 10, and cisplatin 60 mg/m 2 on day 3. PAR levels were measured in peripheral blood mononuclear cells (PBMC). Results: Dose-limiting toxicities (DLT) in two of three patients at DL1 included thrombocytopenia and febrile neutropenia. The protocol was amended to enroll patients treated with ≤2 prior severely myelosuppressive chemotherapy regimens and treated with olaparib 100mgonce daily on days 1 to 4 (DL-1).No DLTs were seen in six patients at DL-1. Because of persistent thrombocytopenia and neutropenia following a return to DL1, patients received 100 mg olaparib every 12 hours on day 1 only. No hematologic DLTs were observed; nonhematologic DLTs included gastrointestinal bleed, syncope, and hypoxia. Of 21 patients evaluable for response, two had partial response. Olaparib inhibited PARP in PBMCs and tumor tissue, although PAR levels were less effectively inhibited when olaparib was used for a short duration. Conclusions: Olaparib in combination with cisplatin and gemcitabine is associated with myelosuppression even at relatively low doses. Modified schedules of olaparib in chemotherapy naive patients will have to be explored with standard doses of chemotherapy.",
author = "Arun Rajan and Carter, {Corey A.} and Kelly, {Ronan Joseph} and Martin Gutierrez and Shivaani Kummar and Eva Szabo and Yancey, {Mary Ann} and Uping Ji and Baskar Mannargudi and Sukyung Woo and Shawn Spencer and Figg, {William Douglas} and Giuseppe Giaccone",
year = "2012",
month = "4",
day = "15",
doi = "10.1158/1078-0432.CCR-11-2425",
language = "English (US)",
volume = "18",
pages = "2344--2351",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "8",

}

TY - JOUR

T1 - A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors

AU - Rajan, Arun

AU - Carter, Corey A.

AU - Kelly, Ronan Joseph

AU - Gutierrez, Martin

AU - Kummar, Shivaani

AU - Szabo, Eva

AU - Yancey, Mary Ann

AU - Ji, Uping

AU - Mannargudi, Baskar

AU - Woo, Sukyung

AU - Spencer, Shawn

AU - Figg, William Douglas

AU - Giaccone, Giuseppe

PY - 2012/4/15

Y1 - 2012/4/15

N2 - Purpose: To determine the safety and tolerability of olaparib with cisplatin and gemcitabine, establish the maximum tolerated dose (MTD), and evaluate the pharmacodynamic and pharmacokinetic profile of the combination. Experimental Design: We conducted a phase I study of olaparib with cisplatin and gemcitabine in patients with advanced solid tumors. Treatment at dose level 1 (DL1) consisted of olaparib 100 mg orally every 12 hours on days 1 to 4, gemcitabine 500 mg/m 2 on days 3 and 10, and cisplatin 60 mg/m 2 on day 3. PAR levels were measured in peripheral blood mononuclear cells (PBMC). Results: Dose-limiting toxicities (DLT) in two of three patients at DL1 included thrombocytopenia and febrile neutropenia. The protocol was amended to enroll patients treated with ≤2 prior severely myelosuppressive chemotherapy regimens and treated with olaparib 100mgonce daily on days 1 to 4 (DL-1).No DLTs were seen in six patients at DL-1. Because of persistent thrombocytopenia and neutropenia following a return to DL1, patients received 100 mg olaparib every 12 hours on day 1 only. No hematologic DLTs were observed; nonhematologic DLTs included gastrointestinal bleed, syncope, and hypoxia. Of 21 patients evaluable for response, two had partial response. Olaparib inhibited PARP in PBMCs and tumor tissue, although PAR levels were less effectively inhibited when olaparib was used for a short duration. Conclusions: Olaparib in combination with cisplatin and gemcitabine is associated with myelosuppression even at relatively low doses. Modified schedules of olaparib in chemotherapy naive patients will have to be explored with standard doses of chemotherapy.

AB - Purpose: To determine the safety and tolerability of olaparib with cisplatin and gemcitabine, establish the maximum tolerated dose (MTD), and evaluate the pharmacodynamic and pharmacokinetic profile of the combination. Experimental Design: We conducted a phase I study of olaparib with cisplatin and gemcitabine in patients with advanced solid tumors. Treatment at dose level 1 (DL1) consisted of olaparib 100 mg orally every 12 hours on days 1 to 4, gemcitabine 500 mg/m 2 on days 3 and 10, and cisplatin 60 mg/m 2 on day 3. PAR levels were measured in peripheral blood mononuclear cells (PBMC). Results: Dose-limiting toxicities (DLT) in two of three patients at DL1 included thrombocytopenia and febrile neutropenia. The protocol was amended to enroll patients treated with ≤2 prior severely myelosuppressive chemotherapy regimens and treated with olaparib 100mgonce daily on days 1 to 4 (DL-1).No DLTs were seen in six patients at DL-1. Because of persistent thrombocytopenia and neutropenia following a return to DL1, patients received 100 mg olaparib every 12 hours on day 1 only. No hematologic DLTs were observed; nonhematologic DLTs included gastrointestinal bleed, syncope, and hypoxia. Of 21 patients evaluable for response, two had partial response. Olaparib inhibited PARP in PBMCs and tumor tissue, although PAR levels were less effectively inhibited when olaparib was used for a short duration. Conclusions: Olaparib in combination with cisplatin and gemcitabine is associated with myelosuppression even at relatively low doses. Modified schedules of olaparib in chemotherapy naive patients will have to be explored with standard doses of chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=84859864115&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859864115&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-11-2425

DO - 10.1158/1078-0432.CCR-11-2425

M3 - Article

C2 - 22371451

AN - SCOPUS:84859864115

VL - 18

SP - 2344

EP - 2351

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 8

ER -